본문 바로가기
KERD
논문KCI 등재

Lithium and Valproate in Bipolar Disorder: From International Evidence-based Guidelines to Clinical Predictors

Calogero Crapanzano|Ilaria Casolaro|Chiara Amendola|Stefano Damiani
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2022.08|Clinical Psychopharmacology and Neuroscience|제20권 제3호|pp. 403-414|DOI 10.9758/cpn.2022.20.3.403

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Bipolar disorderLithiumValproate.

초록

Since decades, lithium and valproate remain the pharmacological cornerstone to treat bipolar disorder. Different response patterns occur according to the phases of illness. At same time, individual pretreatment variables may concur to determine a specific drug-response. Our narrative review focuses on these two key clinical aspects to summarize the state of art. Information from i) clinical trials and ii) the most relevant international guidelines is collected to assess the clinical and preclinical factors that may guide the use of lithium rather than valproate. Lithium may be effective in treating acute mania, and lithium efficacy is maximized when used to prevent both manic and depressive episodes. Lithium may be a better treatment choice in patients with: positive family history for bipolar disorder, mania-depression-interval pattern, few previous affective episodes/hospitalizations, high risk for suicide, no comorbidities. Valproate may be more effective as antimanic rather than prophylactic agent. Valproate might be a better choice in patients with many previous affective episodes/hospitalizations and psychiatric comorbidities. Finally, neither lithium nor valproate are suggested for the treatment of acute mixed states or bipolar depression. To consider clinical and preclinical factors may thus be useful to select the best treatment strategy.

Abstract

Since decades, lithium and valproate remain the pharmacological cornerstone to treat bipolar disorder. Different response patterns occur according to the phases of illness. At same time, individual pretreatment variables may concur to determine a specific drug-response. Our narrative review focuses on these two key clinical aspects to summarize the state of art. Information from i) clinical trials and ii) the most relevant international guidelines is collected to assess the clinical and preclinical factors that may guide the use of lithium rather than valproate. Lithium may be effective in treating acute mania, and lithium efficacy is maximized when used to prevent both manic and depressive episodes. Lithium may be a better treatment choice in patients with: positive family history for bipolar disorder, mania-depression-interval pattern, few previous affective episodes/hospitalizations, high risk for suicide, no comorbidities. Valproate may be more effective as antimanic rather than prophylactic agent. Valproate might be a better choice in patients with many previous affective episodes/hospitalizations and psychiatric comorbidities. Finally, neither lithium nor valproate are suggested for the treatment of acute mixed states or bipolar depression. To consider clinical and preclinical factors may thus be useful to select the best treatment strategy.

참고문헌 (114)

  1. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
  2. Baldessarini R, "Psychotropic medications for patients with bipolar disorder in the United States : polytherapy and adherence", Psychiatr Serv, 59, pp.1175~1183 (2008)
  3. Zivanovic O, "Lithium: a classic drug-frequently discussed, but, sadly, seldom prescribed!", Aust N Z J Psychiatry, 51, pp.886~896 (2017)
  4. Nivoli AM, "Lithium : still a cornerstone in the long-term treatment in bipolar disorder?", Neuropsychobiology, 62, pp.27~35 (2010)
  5. Licht RW, "Lithium : still a major option in the management of bipolar disorder", CNS Neurosci Ther, 18, pp.219~226 (2012)
  6. Post RM, "The new news about lithium : an underutilized treatment in the United States", Neuropsychopharmacology, 43, pp.1174~1179 (2018)
  7. Ng VWS, "Bipolar disorder prevalence and psychotropic medication utilisation in Hong Kong and the United Kingdom", Pharmacoepidemiol Drug Saf, 30, pp.1588~1600 (2021)
  8. Bowden CL, "Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group", JAMA, 271, pp.918~924 (1994)
  9. Bowden C, "A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode", Int Clin Psychopharmacol, 23, pp.254~262 (2008)
  10. Bowden CL, "Efficacy of valproate versus lithium in mania or mixed mania : a randomized, open 12-week trial", Int Clin Psychopharmacol, 25, pp.60~67 (2010)
  11. Clothier J, "Dysphoric mania", J Clin Psychopharmacol, 12(1 Suppl), pp.13~ (1992)[DOI]
  12. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
  13. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders, part II : treatment of mania", World J Biol Psychiatry, 4, pp.5~13 (2003)
  14. Cipriani A, "valproate and divalproex in the maintenance treatment of bipolar disorder", Cochrane Database Syst Rev, 2013, pp.CD003196~ (2013)
  15. Kang MG, "Lithium vs valproate in the maintenance treatment of bipolar I disorder : a post-hoc analysis of a randomized double-blind placebo-controlled trial", Aust N Z J Psychiatry, 54, pp.298~307 (2020)
  16. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)Guidelines for the Biological Treatment of Bipolar Disorders : update 2012 on the longterm treatment of bipolar disorder", World J Biol Psychiatry, 14, pp.154~219 (2013)
  17. Kessing LV, "Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study", Br J Psychiatry, 199, pp.57~63 (2011)
  18. Coombes BJ, "Dissecting clinical heterogeneity of bipolar disorder using multiple polygenic risk scores", Transl Psychiatry, 10, pp.314~ (2020)
  19. O’Connell KS, "Genetic contributions to bipolar disorder : current status and future directions", Psychol Med, 51, pp.2156~2167 (2021)
  20. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)Guidelines for the Biological Treatment of Bipolar Disorders : update 2010 on the treatment of acute bipolar depression", World J Biol Psychiatry, 11, pp.81~109 (2010)
  21. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)Guidelines for the Biological Treatment of Bipolar Disorders : acute and long-term treatment of mixed states in bipolar disorder", World J Biol Psychiatry, 19, pp.2~58 (2018)
  22. National Collaborating Centre for Mental Health (UK), "Bipolar disorder. The NICE guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care", The British Psychological Society and The Royal College of Psychiatrists, ~ (2014)
  23. Fountoulakis KN, "The International College of Neuro-Psychopharmacology(CINP)Treatment Guidelines for Bipolar Disorder in Adults(CINP-BD-2017), part 2 : review, grading of the evidence, and a precise algorithm", Int J Neuropsychopharmacol, 20, pp.121~179 (2017)
  24. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)recommendations for the management of patients with bipolar disorder with mixed presentations", Bipolar Disord, 23, pp.767~788 (2021)
  25. Goodwin GM, "Evidence-based guidelines for treating bipolar disorder : revised third edition recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 30, pp.495~553 (2016)
  26. Poolsup N, "Systematic overview of lithium treatment in acute mania", J Clin Pharm Ther, 25, pp.139~156 (2000)
  27. Cipriani A, "Comparative efficacy and acceptability of antimanic drugs in acute mania : a multiple-treatments meta-analysis", Lancet, 378, pp.1306~1315 (2011)
  28. Pope HG Jr, "Valproate in the treatment of acute mania. A placebo-controlled study", Arch Gen Psychiatry, 48, pp.62~68 (1991)
  29. Bowden CL, "A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania", J Clin Psychiatry, 67, pp.1501~1510 (2006)
  30. Freeman TW, "A double-blind comparison of valproate and lithium in the treatment of acute mania", Am J Psychiatry, 149, pp.108~111 (1992)
  31. Macritchie K, "Valproate for acute mood episodes in bipolar disorder", Cochrane Database Syst Rev, (1), pp.CD004052~ (2003)
  32. Jochim J, "Valproate for acute mania", Cochrane Database Syst Rev, 10, pp.CD004052~ (2019)
  33. Sköld M, "Regional lithium prescription rates and recurrence in bipolar disorder", Int J Bipolar Disord, 9, pp.18~ (2021)
  34. Geddes JR, "Long-term lithium therapy for bipolar disorder : systematic review and meta-analysis of randomized controlled trials", Am J Psychiatry, 161, pp.217~222 (2004)
  35. Severus E, "Lithium for prevention of mood episodes in bipolar disorders : systematic review and meta-analysis", Int J Bipolar Disord, 2, pp.15~ (2014)
  36. Kishi T, "Mood stabilizers and", or antipsychotics for bipolar disorder in the maintenance phase : a systematic review and network meta-analysis of randomized controlled trials, 2021, pp.26, 4146~4157
  37. Yee CS, "Long-term treatment of bipolar disorder with valproate : updated systematic review and meta-analyses", Harv Rev Psychiatry, 29, pp.188~195 (2021)
  38. Kessing LV, "Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations : a systematic review of evidence from observational studies", Bipolar Disord, 20, pp.419~431 (2018)
  39. Miura T, "Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder : a systematic review and network metaanalysis", Lancet Psychiatry, 1, pp.351~359 (2014)
  40. Garnham J, "Prophylactic treatment response in bipolar disorder : results of a naturalistic observation study", J Affect Disord, 104, pp.185~190 (2007)
  41. Rosso G, "Affective recurrences in bipolar disorder after switching from lithium to valproate or vice versa : a series of 57 cases", J Clin Psychopharmacol, 37, pp.278~281 (2017)
  42. BALANCE investigators and collaborators, "Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder(BALANCE) : a randomised open-label trial", Lancet, 375, pp.385~395 (2010)
  43. Hayes JF, "Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records", World Psychiatry, 15, pp.53~58 (2016)
  44. Bohlken J, "Bipolar disorder and outcomes of monotherapy with lithium, valproate, quetiapine, olanzapine, venlafaxine, and citalopram", Pharmacopsychiatry, 54, pp.126~130 (2021)
  45. Bowden CL, "A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group", Arch Gen Psychiatry, 57, pp.481~489 (2000)
  46. Suppes T, "Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder : analysis of two large randomized, placebo-controlled trials", Depress Anxiety, 30, pp.1089~1098 (2013)
  47. McElroy SL, "Dysphoric mania, mixed states, and mania with mixed features specifier : are we mixing things up?", CNS Spectr, 22, pp.170~176 (2017)
  48. Secunda SK, "Diagnosis, state measurement and prediction of treatment response", J Affect Disord, 8, pp.113~121 (1985)
  49. Himmelhoch JM, "Incidence and signficiance of mixed affective states in a bipolar population", Arch Gen Psychiatry, 33, pp.1062~1066 (1976)
  50. Keller MB, "Differential outcome of pure manic, mixed", cycling, and pure depressive episodes in patients with bipolar illness, 1986, pp.255, 3138~3142
  51. Goldberg JF, "Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients", J Clin Psychiatry, 59, pp.151~158 (1998)
  52. Swann AC, "Depression during mania. Treatment response to lithium or divalproex", Arch Gen Psychiatry, 54, pp.37~42 (1997)
  53. Fountoulakis KN, "Treatment of mixed bipolar states", Int J Neuropsychopharmacol, 15, pp.1015~1026 (2012)
  54. Prien RF, "Treatment of mixed mania", J Affect Disord, 15, pp.9~15 (1988)
  55. Backlund L, "Identifying predictors for good lithium response-a retrospective analysis of 100 patients with bipolar disorder using a life-charting method", Eur Psychiatry, 24, pp.171~177 (2009)
  56. Sportiche S, "Clinical factors associated with lithium response in bipolar disorders", Aust N Z J Psychiatry, 51, pp.524~530 (2017)
  57. Woo YS, "Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine : a retrospective study", PLoS One, 15, pp.e0227217~ (2020)
  58. Lee J, "Defining phenotypes of long-term lithium and valproate response, including combination therapy : a modified application of the Alda scale in patients with bipolar disorders", Int J Bipolar Disord, 8, pp.36~ (2020)
  59. Calabrese JR, "Predictors of valproate response in bipolar rapid cycling", J Clin Psychopharmacol, 13, pp.280~283 (1993)
  60. Pfennig A, "Influence of atypical features on the quality of prophylactic effectiveness of long-term lithium treatment in bipolar disorders", Bipolar Disord, 12, pp.390~396 (2010)
  61. Maj M, "Long-term outcome of lithium prophylaxis in bipolar disorder : a 5-year prospective study of 402 patients at a lithium clinic", Am J Psychiatry, 155, pp.30~35 (1998)
  62. Kupka RW, "Rapid and non-rapid cycling bipolar disorder : a metaanalysis of clinical studies", J Clin Psychiatry, 64, pp.1483~1494 (2003)
  63. Hui TP, "A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder", Acta Psychiatr Scand, 140, pp.94~115 (2019)
  64. Grillault Laroche D, "Sociodemographic and clinical predictors of outcome to longterm treatment with lithium in bipolar disorders: a systematic review of the contemporary literature and recommendations from the ISBD", IGSLI Task Force on treatment with lithium, 2020, pp.8, 40~
  65. Kleindienst N, "Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders", Bipolar Disord, 7, pp.404~417 (2005)
  66. Degenhardt EK, "Predictors of relapse or recurrence in bipolar I disorder", J Affect Disord, 136, pp.733~739 (2012)
  67. Swann AC, "Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania", Am J Psychiatry, 156, pp.1264~1266 (1999)
  68. Swann AC, "Mania : differential effects of previous depressive and manic episodes on response to treatment", Acta Psychiatr Scand, 101, pp.444~451 (2000)
  69. Gyulai L, "Maintenance efficacy of divalproex in the prevention of bipolar depression", Neuropsychopharmacology, 28, pp.1374~1382 (2003)
  70. Frankenburg FR, "Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder : a double-blind placebo-controlled pilot study", J Clin Psychiatry, 63, pp.442~446 (2002)
  71. O’Connell RA, "Outcome of bipolar disorder on long-term treatment with lithium", Br J Psychiatry, 159, pp.123~129 (1991)
  72. Salloum IM, "Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism : a double-blind placebo-controlled study", Arch Gen Psychiatry, 62, pp.37~45 (2005)
  73. Young LT, "Anxious and non-anxious bipolar disorder", J Affect Disord, 29, pp.49~52 (1993)
  74. Keller MB, "Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium", Arch Gen Psychiatry, 49, pp.371~376 (1992)
  75. Maj M, "Factors associated with response to lithium prophylaxis in DSM III major depression and bipolar disorder", Pharmacopsychiatry, 18, pp.309~313 (1985)
  76. Grof P, "Is response to prophylactic lithium a familial trait?", J Clin Psychiatry, 63, pp.942~947 (2002)
  77. Grof P, "Lithium response and genetics of affective disorders", J Affect Disord, 32, pp.85~95 (1994)
  78. Mendlewicz J, "Relationship between the effectiveness of lithium therapy and family history", Am J Psychiatry, 130, pp.1011~1013 (1973)
  79. Duffy A, "A consecutive series of treated affected offspring of parents with bipolar disorder : is response associated with the clinical profile?", Can J Psychiatry, 52, pp.369~376 (2007)
  80. Coryell W, "Family history and symptom levels during treatment for bipolar I affective disorder", Biol Psychiatry, 47, pp.1034~1042 (2000)
  81. Yazici O, "Predictors of lithium prophylaxis in bipolar patients", J Affect Disord, 55, pp.133~142 (1999)
  82. Masui T, "A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.204~208 (2008)
  83. Sarantidis D, "Predictors of lithium prophylaxis effectiveness", Prog Neuropsychopharmacol, 5, pp.507~510 (1981)
  84. Dunner DL, "Clinical factors in lithium carbonate prophylaxis failure", Arch Gen Psychiatry, 30, pp.229~233 (1974)
  85. Yang YY, "Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients", Acta Psychiatr Scand, 71, pp.171~175 (1985)
  86. Rybakowski JK, "Response to lithium prophylaxis : interaction between serotonin transporter and BDNF genes", Am J Med Genet B Neuropsychiatr Genet, 144B, pp.820~823 (2007)
  87. Okuma T, "Effects of carbamazepine and lithium on affective disorders", Neuropsychobiology, 27, pp.138~145 (1993)
  88. Maj M, "Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder : a prospective study", Pharmacopsychiatry, 19, pp.420~423 (1986)
  89. Bowden CL, "A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder", J Clin Psychiatry, 66, pp.111~121 (2005)
  90. Rosenthal NE, "Psychosis as a predictor of response to lithium maintenance treatment in bipolar affective disorder", J Affect Disord, 1, pp.237~245 (1979)
  91. Tohen M, "Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis", Arch Gen Psychiatry, 47, pp.1106~1111 (1990)
  92. Cipriani A, "Lithium in the prevention of suicide in mood disorders : updated systematic review and meta-analysis", BMJ, 346, pp.f3646~ (2013)
  93. Song J, "Suicidal behavior during lithium and valproate treatment : a within-individual 8-year prospective study of 50, 000patients with bipolar disorder", Am J Psychiatry, 174, pp.795~802 (2017)
  94. Antolín-Concha D, "Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder : a Finnish nationwide cohort study", J Affect Disord, 277, pp.885~892 (2020)
  95. Ragazan DC, "Sex-specific associations between bipolar disorder pharmacological maintenance therapies and inpatient rehospitalizations : a 9-year Swedish national registry study", Front Psychiatry, 11, pp.598946~ (2020)
  96. Alda M, "The phenotypic spectra of bipolar disorder", Eur Neuropsychopharmacol, 14(Suppl 2), pp.S94~S99 (2004)
  97. Cade JF, "Lithium salts in the treatment of psychotic excitement", Med J Aust, 2, pp.349~352 (1949)
  98. Lempérière T, "Brief history of the development of valproate in bipolar disorders", Encephale, 27, pp.365~372 (2001)
  99. Lähteenvuo M, "Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder", JAMA Psychiatry, 75, pp.347~355 (2018)
  100. Del Matto L, "Lithium and suicide prevention in mood disorders and in the general population : a systematic review", Neurosci Biobehav Rev, 116, pp.142~153 (2020)
  101. Judd LL, "Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders", J Affect Disord, 108, pp.49~58 (2008)
  102. Perlis RH, "Predictors of recurrence in bipolar disorder : primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder(STEP-BD)", Am J Psychiatry, 163, pp.217~224 (2006)
  103. Simon NM, "Anxiety disorder comorbidity in bipolar disorder patients : data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder(STEP-BD)", Am J Psychiatry, 161, pp.2222~2229 (2004)
  104. Coryell W, "The significance of psychotic features in manic episodes : a report from the NIMH collaborative study", J Affect Disord, 67, pp.79~88 (2001)
  105. Ozyildirim I, "Impact of psychotic features on morbidity and course of illness in patients with bipolar disorder", Eur Psychiatry, 25, pp.47~51 (2010)
  106. Canuso CM, "Psychotic symptoms in patients with bipolar mania", J Affect Disord, 111, pp.164~169 (2008)
  107. Post RM, "Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood", J Clin Psychiatry, 71, pp.864~872 (2010)
  108. Hantouche EG, "Clinical and psychometric characterization of depression in mixed mania : a report from the French National Cohort of 1090 manic patients", J Affect Disord, 96, pp.225~232 (2006)
  109. Perugi G, "Polarity of the first episode, clinical characteristics, and course of manic depressive illness : a systematic retrospective investigation of 320 bipolar I patients", Compr Psychiatry, 41, pp.13~18 (2000)
  110. Kupfer DJ, "Stabilization in the treatment of mania, depression and mixed states", Acta Neuropsychiatr, 12, pp.110~114 (2000)
  111. Maj M, "Validity of rapid cycling as a course specifier for bipolar disorder", Am J Psychiatry, 151, pp.1015~1019 (1994)
  112. Tondo L, "Rapid-cycling bipolar disorder : effects of long-term treatments", Acta Psychiatr Scand, 108, pp.4~14 (2003)
  113. Patel RS, "Bipolar disorder and comorbid borderline personality disorder: patient characteristics and outcomes in US hospitals", Medicina(Kaunas), 55, pp.13~ (2019)
  114. Simhandl C, "A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients", J Clin Psychiatry, 75, pp.254~262 (2014)

관련 논문AI추천

Pharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based ApproachAther Muneer대한가정의학회 · Korean Journal of Family Medicine2016 · 제37권 제3호Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines이정구, 전덕인, Bo-Hyun Yoon, Hoo-Rim Song, Inki Sohn, Jeong Seok Seo, Jong Hyun Jeong, Kyung Joon Min, Moon Doo Kim, Se-Hoon Shim, Won Kim, Won-Myong Bahk, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2019 · 제17권 제2호Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar DisorderAtsuo Nakagawa, Eiichi Katsumoto, Eiichiro Goto, Hitoshi Ueda, Kazuhira Miki, Kazutaka Shimoda, Koichiro Watanabe, Koji Edagawa, Masaki Kato, Naoto Adachi, Norio Yasui-Furukori, Reiji Yoshimura, Seiji Hongo, Takaharu Azekawa, Takashi Tsuboi, Toshiaki Kikuchi, Yukihisa Kubota대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2020 · 제18권 제4호Neuromolecular Etiology of Bipolar Disorder: Possible Therapeutic Targets of Mood Stabilizers박성우, 박원명, 이정구, Dae-Hyun Seog, Mi Kyoung Seo, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2022 · 제20권 제2호Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines김문두, 박원명, 심세훈, 전덕인, 정종현, 추일한, Bo-Hyun Yoon, Chan-Mo Yang, Inki Sohn, Jeong Seok Seo, Jung Goo Lee, Myung Hun Jung, Sung-Yong Park, Won Kim, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2023 · 제21권 제1호Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision송후림, Bo-Hyun Yoon, Duk-In Jon, Inki Sohn, Jeong Seok Seo, Jong Hyun Jeong, Jung Goo Lee, Kyung Joon Min, Moon Doo Kim, Se-Hoon Shim, Won Kim, Won-Myong Bahk, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2018 · 제16권 제4호

이 간행물의 다른 논문 (19건)

Alterations of Power Spectral Density in Salience Network during Thought-action Fusion Induction Paradigm in Obsessive-compulsive DisorderHeajung Choi, Tae Yang Jang, Sang Won Lee, Eunji Kim, Seungho Kim, 송희진, 이승재, Yongmin Chang, Moon Jung Hwangpp. 415-426Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical SettingWilson Tan, Paul Bergmans, Ahmad Hatim Sulaiman, Young-Chul Chung, Yen Kuang Yangpp. 427-439Apnea-hypopnea Index is Correlated with Pulse Rate in Patients with Sleep-related Breathing Disorder without Hypertension, Cardiovascular Disease, or Diabetes MellitusKwang-Pil Ko, 김지언, 강승걸, 신승헌, Seo-Eun Cho, 문정근, Jae Hyoung Park, Jae-Kean Ryupp. 440-449Machine-Learning for Prescription Patterns: Random Forest in the Prediction of Dose and Number of Antipsychotics Prescribed to People with SchizophreniaMattia Marchi, Giacomo Galli, Gianluca Fiore, Andrew Mackinnon, Giorgio Mattei, Fabrizio Starace, Gian M. Galeazzipp. 450-461Methylome-wide Association Study of Patients with Recent-onset PsychosisYin Cui, Yan-Hong Piao, Young-Chul Chung, Sung-Wan Kim, Ling Li, Bong Ju Lee, Jung-Jin Kim, Shi Hyun Kang, Maryam Karamikheirabad, Fatima Zahra Ramipp. 462-473
원문 보기